الفهرس 
Significance of CD200 expression in patients with acute myeloid leukemia and its correlation with other prognostic markers
ContentsOnly 14 pages are availabe for public view
 |  | from | 111 |  |  |
| | | from | 111 | | |
Abstract
Acute myeloid leukemia (AML) is a heterogeneous group of diseases characterized by uncontrolled proliferation of hematopoietic progenitor cells with arrest of maturation and disruption of normal hematopoiesis. CD200 is a protein belongs to immunoglobulin superfamily, it has an immunosuppressant effect by interacting with its receptor (CD200R). We studied the expression of CD200 on 74 patients diagnosed with AML, to evaluate the impact of CD200 expression on outcome and its possible association with other known prognostic markers.CD200 was found in 49/74 (66.2%) patients, CD200 was more expressed in CD34 positive cases (P= 0.009) and cases with gum hyperplasia (P= 0.022). Trend relation with inv(16) (P= 0.085) and with myeloid with monocytic phenotype ( P=0.085).In conclusion, our data did not confirm the negative prognostic impact of CD200 expression on outcome and survival of patients. CD200 may be incorporated in to the initial diagnostic work-up in patients treated within clinical trials for discovery of new therapy which target malignant leukemic cells without harming other cells